# Real-world Clinical Effectiveness and Patient Insight Associated With Adding Sodium Glucose Co-transporter 2 Inhibitor to Gliclazide Modified Release

> **NCT06708091** · — · COMPLETED · sponsor: **Servier Affaires Médicales** · enrollment: 537 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06708091
- **Lead sponsor:** Servier Affaires Médicales
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-15
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 537 (ACTUAL)
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06708091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06708091, "Real-world Clinical Effectiveness and Patient Insight Associated With Adding Sodium Glucose Co-transporter 2 Inhibitor to Gliclazide Modified Release". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06708091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*